Land: Israel
Språk: engelska
Källa: Ministry of Health
EPTIFIBATIDE
MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL
B01AC16
SOLUTION FOR INJECTION
EPTIFIBATIDE 2 MG/ML
I.V
Required
SCHERING-PLOUGH LABO. N.V , BELGIUM
EPTIFIBATIDE
EPTIFIBATIDE
Integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. Integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. Integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). Integrilin is intended for use with aspirin and heparin.
2013-10-31
אפורל ןולעב )תוחיטב עדימ ( הרמחה לע העדוה :ךיראת 12 רבמבונב 2014 :תילגנאב רישכת םש INTEGRILIN 0.75 MG/ML. 2 MG/ML :םושיר רפסמ 112-71-29528-11 , 112-72-29529-11 :םושירה לעב םש -לארשי( םהודו פראש קרמ תרבח 1996 מ"עב ) תושקובמה תורמחהה אפורל ןולעב קרפ יחכונ טסקט שדח טסקט CONTRAINDICATIONS Known hypersensitivity to any component of the product. Hypersensitivity to INTEGRILIN or any component of the product hypersensitivity reactions that occurred included anaphylaxis and urticaria). WARNINGS AND PRECAUTIONS- _Bleeding_ Because eptifibatide inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostasis, including thrombolytics, oral anticoagulants, nonsteroidal anti- inflammatory drugs, and dipyridamole. To avoid potentially additive pharmacologic effects, concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided _Use of Thrombolytics, _ _Anticoagulants, and Other _ _Antiplatelet Agents-_ Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti- inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT _[see Dosage _ _and Administration (2)]_. WARNINGS AND PRECAUTIONS- _Thrombocytopenia_ In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue INTEGRILIN and heparin (unfractionated or low- molecular-weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate (see ADVERSE REACTIONS, Immunogenicity). There has been no clinical experience with eptifibat Läs hela dokumentet
1 PRESCRIBING INFORMATION INTEGRILIN ® 0.75 MG/ML SOLUTION FOR I.V. INFUSION INTEGRILIN ® 2 MG/ML SOLUTION FOR I.V. INJECTION ( EPTIFIBATIDE) 1 INDICATIONS AND USAGE INTEGRILIN is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. INTEGRILIN is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. INTEGRILIN is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atherectomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myocardial infarction, need for urgent intervention). INTEGRILIN is intended for use with aspirin and heparin. 2 DOSAGE AND ADMINISTRATION Before infusion of INTEGRILIN, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. 2.1 DOSAGE IN ACUTE CORONARY SYNDROME (ACS) INDICATION NORMAL RENAL FUNCTION CREATININE CLEARANCE LESS THAN 50 ML/MIN Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min • Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours • If a patient is to undergo PCI, the infusion Läs hela dokumentet